Investment Rating - The report assigns an investment rating of "Outperform the Market" for the pharmaceutical sector, indicating a relative performance better than the benchmark index [8]. Core Insights - The pharmaceutical sector has shown resilience, with the SW Pharmaceutical Bio Index declining only 0.14% compared to the Shanghai and Shenzhen 300 Index's decline of 0.28% during the week of December 15-21 [2]. - The report highlights significant developments in AI healthcare, particularly with the launch of Ant Group's upgraded AI health app "Antifufu," which aims to enhance health management for users [2]. - Insilico Medicine's IPO is anticipated to drive innovation in drug development, with a focus on its AI-driven platform Pharma.AI and promising clinical results for its lead product Rentosertib [2]. - The approval of the Enhertu and trastuzumab combination therapy for HER2-positive breast cancer is expected to redefine first-line treatment standards in this area [2]. - The report emphasizes the potential of Chinese innovative drugs in international markets and suggests continued monitoring of key sectors such as ADCs, bispecific antibodies, and weight-loss drugs [2]. Summary by Sections Industry Performance - The pharmaceutical sector's weekly trading volume was 389.82 billion yuan, showing a slight decline compared to previous weeks, indicating a need for recovery in market sentiment [2]. AI Healthcare Developments - The "Antifufu" app connects users with 300,000 real doctors for online consultations and has over 15 million monthly active users, with 55% from lower-tier cities, showcasing the app's broad reach [2]. IPO and Drug Development - Insilico Medicine's IPO is set for December 30, with a total fundraising target of 2.277 billion HKD, primarily for clinical research of its drug pipeline [2][5]. Treatment Innovations - The Enhertu and trastuzumab combination therapy has shown a significant improvement in progression-free survival rates, marking a major advancement in treatment options for HER2-positive breast cancer [2].

Quantum Technology - The Australian team has developed an 11-qubit silicon-based processor, achieving high-fidelity entanglement across dual-core spin registers, marking a significant academic breakthrough in silicon quantum computing [9][10][12] - The Canadian government has launched the Quantum Leaders Program (CQCP) with an investment of up to CAD 92 million to support local companies in developing industrial-grade fault-tolerant quantum computers [10][11] - The global quantum industry is entering a phase of "technology route differentiation and ecological collaboration," with major players like IBM and Google making significant advancements in superconducting and quantum error correction technologies [13] Biomanufacturing - The AI-driven pharmaceutical company Insilico Medicine is set to go public on the Hong Kong Stock Exchange, aiming to raise HKD 2.277 billion, leveraging its Pharma.AI platform for end-to-end drug development [14][16] - The Ministry of Industry and Information Technology has released key lists at the 2025 Biomanufacturing Conference, highlighting 28 high-performance bioreactor innovation units and 43 pilot capacity construction platforms [23] Hydrogen Energy and Nuclear Fusion - The Chinese government emphasizes expanding green electricity applications and fostering hydrogen energy as part of its dual carbon goals, with a focus on developing new growth points [25][26] - China Energy Construction has launched the world's largest green hydrogen and ammonia integration project in Jilin, with a total investment of CNY 29.6 billion [34][36] - Trump Media Technology Group has announced a merger with TAE Technologies, aiming to build the world's first commercial nuclear fusion power plant with a capacity of 50 MW by 2026 [33] Brain-Computer Interfaces - The Chinese Academy of Sciences has completed a second invasive brain-computer interface clinical trial, allowing a high-level paraplegic patient to control smart devices using brain signals [40][41] - BrainCo Technology has successfully completed the first clinical trial of its fully implanted brain-computer interface product, which features an internal battery and wireless capabilities [42][43] - The National Medical Products Administration has held a meeting to promote the development of brain-computer interface medical devices, emphasizing safety and effectiveness [47] Embodied Intelligence - The Ministry of Industry and Information Technology has issued the first L3 autonomous driving production permits, allowing specific electric vehicle models to conduct trials in designated areas [49] - Daxiao Robotics has launched the open-source "Kairos 3.0" model, which utilizes human-centric data collection techniques to enhance the development of embodied intelligence [50][52] - Moer Thread has introduced a simulation training platform for embodied intelligence, integrating various technologies to improve development efficiency [53] Sixth Generation Mobile Communication (6G) - The 4th 6G Frontier Technology and Trends Forum was held in Beijing, where multiple organizations signed agreements to collaborate on technology sharing and joint research to accelerate the development of the 6G industry [55]

Core Viewpoint - The Hong Kong stock market is entering a significant phase for annual IPOs, with six companies launching their offerings and scheduled to list on December 30, reflecting a strong demand for quality enterprises to utilize market opportunities [1][2]. Group 1: Companies and Their Offerings - Six companies, including Insilico Medicine, Wuyishijie, Xunce, Meilian Holdings, Woan Robotics, and Linqingxuan, are set to launch IPOs, covering diverse sectors such as AI pharmaceuticals, digital twins, home robotics, and high-end skincare [1][2]. - Insilico Medicine, known as a pioneer in AI pharmaceuticals, has set its IPO price at HKD 24.05, aiming to raise HKD 2.277 billion, making it the largest among the six [1]. - Wuyishijie, focusing on digital twin and Physical AI technologies, plans to issue 23.975 million shares at HKD 30.5 each, with a potential fundraising of up to HKD 841 million if the over-allotment option is exercised [2]. - Xunce, a real-time data infrastructure service provider, is expected to raise between HKD 1.08 billion and HKD 1.23 billion, with a share price range of HKD 48-55 [2]. - Woan Robotics, backed by industry figure Li Zexiang, is entering the home robotics sector, while Linqingxuan is offering 13.96645 million shares at HKD 77.77 each [2]. Group 2: Market Trends and Analysis - The concentration of tech and new consumer companies in the IPO market indicates a shift in the structure of IPOs, with technology and new consumption becoming the dominant forces [1][3]. - The traditional industrial sector, represented by Meilian Holdings, highlights the financing needs of transforming traditional industries, aligning with the "technology-led, diversified supplement" structure of the Hong Kong IPO market [3]. - The influx of new IPOs may lead to market differentiation, where the quality of cornerstone investors and the ability to deliver on performance will be critical in distinguishing the companies [3]. - The simultaneous issuance of multiple new stocks may create a fund diversion effect, impacting the demand for public offerings and international placements [3].

New IPOs - The largest biotech IPO in Hong Kong for 2025 is initiated by Insilico Medicine (03696), which boasts the fastest global progress in AI drug development [1] - Lin Qingxuan (02657) will conduct its IPO from December 18 to December 23, attracting cornerstone investors like Fidelity [1] - Woan Robotics (06600) is set to launch its IPO during the same period, with an expected listing date of December 30 [1] - Meilian Holdings (02671) and Wuyi Vision (06651) will also hold their IPOs from December 18 to December 23, both expected to list on December 30 [1] - Xun Ce (03317) will follow the same IPO schedule, with a listing anticipated on December 30 [1] - Zhihui Mining (02546) achieved a remarkable 5248.15 times subscription in its public offering, with a listing date of December 19 [1] - China National Airlines (00753) plans to invest in Shenzhen Airlines' equity financing, with Kunhang Investment, a state-owned entity, being shortlisted [1] - Sensetime-W (00020) intends to place 1.75 billion new Class B shares, aiming to raise approximately HKD 3.146 billion [1] - Fosun Pharma (02196) is enhancing its overseas innovative drug strategy by signing a cooperation and option agreement with Clavis Bio [1] - WuXi AppTec (02359) invested around EUR 30 million to acquire a 3.22% stake in a French biopharmaceutical fund [1] - Minhua Holdings (01999) plans to acquire 100% equity in the American soft furniture company Gainline Recline Intermediate Corp [1] Share Buybacks - Tencent Holdings (00700) repurchased 1.055 million shares for HKD 636 million on December 18 [2] - Xiaomi Group-W (01810) spent HKD 151 million to buy back 3.75 million shares on the same day [2] - COSCO Shipping Holdings (01919) repurchased 5.9 million shares for HKD 80.557 million [2] - Country Garden Services (06098) bought back 2.7 million shares for HKD 17.136 million [2] - Jiangsu Ninghu Expressway (00177) saw an increase of 52.862 million shares by Yunsong Capital [2]

Investment Rating - The report recommends subscription for the IPO of the company, indicating a positive investment outlook [1]. Core Insights - The company, established in 2014, operates as a global AI-driven drug discovery and development firm, leveraging its proprietary Pharma.AI platform to generate over 20 clinical or IND-stage assets, with three assets licensed to international pharmaceutical companies, totaling a contract value of up to $2.1 billion [2]. - The company employs a project-based business model, primarily generating revenue through licensing and collaboration agreements, and aims to expand the application of Pharma.AI into various industries, including advanced materials, agriculture, nutrition products, and veterinary medicine [2]. - The AI drug discovery and development (AIDD) market is projected to grow from $11.9 billion in 2023 to $74.6 billion by 2032, with a compound annual growth rate (CAGR) of 22.6%, positioning the company as a leader in this rapidly growing sector [3]. Financial Performance - The company is currently in the R&D phase, with revenue increasing from $3.01 million in 2022 to $5.12 million in 2023, and further projected to rise to $8.58 million in 2024. For the first half of 2025, revenue was reported at $2.75 million [3]. - Net losses have decreased over the years, with losses of $22.18 million in 2022, $21.16 million in 2023, $1.71 million in 2024, and $1.92 million in the first half of 2025, indicating improving financial health [3]. - The expected market capitalization post-IPO is estimated at HKD 13.4 billion, reflecting the company's potential as a leading player in the domestic AI pharmaceutical sector [3].

Group 1: IPO Information - The IPO for 英矽智能 (03696.HK) is open for subscription from December 18 to December 23, with a global offering of 94,690,500 shares, where 10% is for public offering in Hong Kong and 90% for international offering. The offer price is set at HKD 24.05 per share, with a minimum investment of HKD 12,146.27 for 500 shares [2][4] - The IPO for 五一视界 (06651.HK) is also open for subscription from December 18 to December 23, with a global offering of 23,975,200 shares, where 5% is for public offering in Hong Kong and 95% for international offering. The offer price is set at HKD 30.50 per share, with a minimum investment of HKD 6,161.51 for 200 shares [8][10] - 迅策 (03317.HK) is offering 22,500,000 shares from December 18 to December 23, with 10% for public offering in Hong Kong and 90% for international offering. The price range is HKD 48.00 to HKD 55.00 per share, with a minimum investment of HKD 5,555.47 for 100 shares [13][15] - 美联股份 (02671.HK) is offering 24,600,000 shares from December 18 to December 23, with 10% for public offering in Hong Kong and 90% for international offering. The price range is HKD 7.10 to HKD 9.16 per share, with a minimum investment of HKD 2,775.71 for 300 shares [19][21] - 卧安机器人 (06600.HK) is offering 22,222,300 shares from December 18 to December 23, with 10% for public offering in Hong Kong and 90% for international offering. The price range is HKD 63.00 to HKD 81.00 per share, with a minimum investment of HKD 8,181.69 for 100 shares [25][27] - 林清轩 (02657.HK) is offering 13,966,500 shares from December 18 to December 23, with 10% for public offering in Hong Kong and 90% for international offering. The offer price is set at HKD 77.77 per share, with a minimum investment of HKD 3,927.72 for 50 shares [30][32] Group 2: Financial Performance - 英矽智能 reported revenues of USD 30.15 million, USD 51.18 million, USD 85.83 million, USD 59.69 million, and USD 27.46 million for the years 2022, 2023, 2024, and the six months ending June 30, 2025, respectively. The net losses for the same periods were USD 221.83 million, USD 211.64 million, USD 17.10 million, USD 8.03 million, and USD 19.22 million [7] - 五一视界's revenue grew from RMB 169.98 million in 2022 to RMB 256.30 million in 2023, and further to RMB 287.36 million in 2024. The revenue for the six months ending June 30, 2025, was RMB 53.82 million, showing a 62.0% increase from the same period in 2024. The net losses for the same periods were RMB 189.79 million, RMB 87.08 million, RMB 78.97 million, RMB 65.07 million, and RMB 94.05 million [12][12] - 迅策's revenue for the years 2022, 2023, and 2024 was RMB 288 million, RMB 530 million, and RMB 632 million, respectively, with net losses of RMB 97 million, RMB 63 million, and RMB 98 million for the same years [18] - 美联股份 reported revenues of RMB 1,902.84 million, RMB 1,453.18 million, RMB 1,523.03 million, RMB 509.51 million, and RMB 1,424.11 million for the years 2022, 2023, 2024, and the six months ending June 30, 2025, respectively. The net profits for the same periods were RMB 87.71 million, RMB 62.13 million, RMB 70.78 million, RMB 13.61 million, and RMB 62.63 million [23] - 卧安机器人的 revenue for the years 2022, 2023, and 2024 was RMB 274.60 million, RMB 457.26 million, and RMB 609.92 million, respectively, with net losses of RMB 86.98 million, RMB 16.38 million, and RMB 3.07 million. The company reported a net profit of RMB 27.90 million for the six months ending June 30, 2025 [29][29] - 林清轩's total revenue for the years 2022, 2023, 2024, and the six months ending June 30, 2025, was RMB 691.15 million, RMB 805.00 million, RMB 1,209.64 million, RMB 530.45 million, and RMB 1,051.77 million, respectively. The company transitioned from a net loss of RMB 5.93 million in 2022 to a net profit of RMB 84.52 million in 2023 and further increased to RMB 186.83 million in 2024 [34]

今年以来，AI、生物医药均是港股市场爆火的板块，阿里巴巴（09988.HK）、百济神州（06160.HK）、信达生物（01801.HK）等概念股实现大涨。 公告披露，英矽智能拟将募资净额投往这些方向：约48.0%用于为关键临床阶段管线候选药物的进一步临床研发提供资金；约15.0%用于开发新的生成式AI 模型及相关验证研究工作；约12.0%用于进一步开发及扩展自动化实验室；约20.0%用于早期药物发现及开发（包括其他管线候选药物的临床前及临床阶 段）的研发资金；约5.0%用于营运资金及一般公司用途。 值得一提的是，英矽智能此次发行获得了众多知名基石投资者的支持，包括腾讯（00700.HK）、Oaktree、Schroders、淡马锡、瑞银、华夏基金、中国太 保、易方达基金管理等。在满足相关条件后，基石投资者或其指定实体认购总金额为1.15亿美元的首次公开募股。 而在12月18日，有一只叠加了AI、生物医药双重概念的企业——英矽智能（03696.HK）在港股市场开启了招股。 根据全球发售资料，英矽智能招股时间为18日至23日，预期将于12月30日上市。 英矽智能此次全球发售约9469.05万股股份（视乎超额配股权 ...

Group 1 - The company plans to globally offer 94.69 million shares, with 9.47 million shares available in Hong Kong and 85.22 million shares for international sale, along with an over-allotment option of 14.20 million shares [1] - The subscription period is set from December 18 to December 23, with a maximum offer price of HKD 24.05 per share and an entry fee of approximately HKD 12,146.27 for 500 shares [1] - The total expected fundraising amount is HKD 2.277 billion, with a net amount of HKD 2.026 billion, which will be used for further clinical research and development of key pipeline candidates, early drug discovery, generative AI model development, and operational funding [1] Group 2 - The company is expected to be listed on the main board by December 30, 2025, with Morgan Stanley, CICC, and GF Securities serving as joint sponsors [2] - Established in 2014, the company is recognized as a reputable AI-driven biotechnology firm with a global presence [2] - The projected net profits for the fiscal years 2023, 2024, and the first half of 2025 are -USD 212 million, -USD 17.1 million, and -USD 19.2 million, reflecting year-on-year changes of 4.59%, 91.92%, and -339.29% respectively [2]

Core Viewpoint - The Hong Kong capital market is experiencing a concentrated IPO wave with six companies from various industries launching public offerings, showcasing trends in new economic sectors such as artificial intelligence, biotechnology, and high-end consumer goods [1] Group 1: Companies and Their Offerings - Insilico Medicine is set to launch the largest Biotech IPO in the Hong Kong market for 2025, planning to issue approximately 94.69 million shares at a price of HKD 24.05 per share, leveraging its Pharma.AI platform for over 30 innovative projects in oncology, immunology, fibrosis, and metabolism [2][3] - Five One Vision, recognized as the "first Physical AI stock," aims to sell 23.975 million shares globally, with a price of HKD 30.5 per share, potentially raising up to HKD 841 million if the over-allotment option is exercised [2][3] - XunCe, a leading provider of real-time data infrastructure and analytics solutions in China's asset management sector, plans to issue 22.5 million shares with a price range of HKD 48-55 per share [3] - Meilian Holdings, a major service provider in China's prefabricated steel structure construction market, intends to issue 24.6 million shares at a price range of HKD 7.10-9.16 per share [3] - Woan Robotics, a global provider of home robotic systems, plans to issue 22.2223 million shares at a price range of HKD 63-81 per share [3] - Lin Qingxuan, a representative of high-end domestic skincare products in China, aims to issue 13.9665 million shares at a price of HKD 77.77 per share [3] Group 2: Market Position and Investment - Insilico Medicine has attracted a strong base of cornerstone investors, including Eli Lilly, Tencent, Temasek, Schroders, UBS, and Oak Tree Capital, along with a robust pre-IPO investment lineup featuring notable firms like Warburg Pincus and Sequoia China [2] - Five One Vision has established a comprehensive technological capability in Physical AI, supported by significant investments from leading firms such as Moolec Science and SenseTime, as well as prominent individual investors [3] - XunCe holds an 11.6% market share in China's real-time data infrastructure and analytics market, ranking first in the asset management sector as of 2024 [3] - Meilian Holdings ranks third in the prefabricated steel structure construction market in China with a market share of 3.5% [3] - Woan Robotics targets markets in Japan, Europe, and North America, focusing on advanced robotic systems [3] - Lin Qingxuan's core product, camellia oil essence, has been the top-selling facial essence oil in China for 11 consecutive years since 2014 [3]

Group 1 - The company plans to globally offer 94.69 million shares, with 9.47 million shares available in Hong Kong and 85.22 million shares for international sale, along with an over-allotment option of 14.20 million shares [1] - The subscription period is set from December 18 to December 23, with a maximum offer price of HKD 24.05 per share and an entry fee of approximately HKD 12,146.27 for 500 shares [1] - The total expected fundraising amount is HKD 2.277 billion, with a net amount of HKD 2.026 billion, which will be used for further clinical research and development of key pipeline candidates, early drug discovery, generative AI model development, and operational funding [1] Group 2 - The company is expected to be listed on the main board by December 30, 2025, with Morgan Stanley, CICC, and GF Securities as joint sponsors [2] - Established in 2014, the company is recognized as a reputable AI-driven biotechnology firm with a global presence [2] - The net profits for the fiscal years 2023, 2024, and the first half of 2025 are projected to be -$212 million, -$17.096 million, and -$19.215 million respectively, with year-on-year changes of 4.59%, 91.92%, and -339.29% [2]